Clinical Targets
Exploratory target areas for partner-led development.
MTRX candidate formats are organized around clinical target areas where route selection, delivery architecture, dose control and lipophilic active formulation may be strategically relevant. The lead therapeutic category is Autoimmune Disorders, anchored by atopic dermatitis-oriented topical development.
Development target map.
Autoimmune DisordersLead category. Atopic dermatitis is the initial flagship target, supported by broader immune-mediated dermatology concepts including pruritus, inflammatory dermatoses, compromised barrier models and psoriasis-supportive development tracks.
MTRX-201 / 202 / 203Pain and inflammation-oriented developmentLocalized musculoskeletal discomfort, peripheral inflammatory pain models, neuropathic pain exploratory models and topical/oral cannabinoid combinations.
MTRX-301 / 102Neurology / CNS-supportive cannabinoid developmentDose-ranging CBD programs, CBN sleep-oriented exploration, spasticity-supportive combinations and other CNS-oriented partner pathways.
MTRX-101 / 301 / 401Oncology supportive careNausea/appetite supportive pathways, cancer-related pain supportive models and radiodermatitis-oriented topical development concepts.
MTRX-102 / 201 / 301Women’s health and localized inflammatory conditionsLocalized irritation, pelvic discomfort support models and sensitive-skin topical development concepts.
Future topical seriesFrom active to solid-state delivery.
Each candidate format follows the same route — lipophilic active, MTRX incorporation, solid-state conversion and aqueous activation — mapped to route-specific development and clinical target strategies.
